Results of a trial of combined propamidine isethionate and neomycin therapy for acanthamoeba keratitis

Sylvia L. Hargrave, James P McCulley, Ziad Husseini

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Purpose: To characterize patients with Acanthamoeba keratitis and to evaluate the safety and efficacy of propamidine isethionate 0.1% ophthalmic solution (Brolene) when administered concomitantly with neomycin- polymyxin B-gramicidin ophthalmic solution (Neotricin) in the treatment of Acanthamoeba keratitis. Design: Prospective, noncomparative case series. Methods: The authors report the clinical characteristics and outcomes of patients who entered this multi-centered, open-label, clinical trial. Eighty-three patients with Acanthamoeba keratitis representing 87 infected eyes entered the trial. Results: Sixty (69%) of the 87 eyes enrolled had data analyzed for treatment efficacy and safety. Of these 60 eyes, 50 (83%) experienced treatment success. Thirty (60%) patients successfully treated adhered to treatment protocol guidelines. Patients who broke protocol had disease exacerbation during the maintenance therapy phase. The only eyes lost/enucleated were 7 of 17 in which penetrating keratoplasty was performed before eradication of the infectious agent. Conclusion: Propamidine isethionate and neomycin are an effective treatment for Acanthamoeba keratitis. Penetrating keratoplasty should be performed only for visual rehabilitation and not to 'debulk' an active infection. The authors advocate treating patients with topical medications, mainly Brolene, until all organisms are eradicated. There should be no signs of infection for at least 3 months in the patients not receiving antiamebic medications before penetrating keratoplasty is performed.

Original languageEnglish (US)
Pages (from-to)952-957
Number of pages6
JournalOphthalmology
Volume106
Issue number5
StatePublished - May 1 1999

Fingerprint

Acanthamoeba Keratitis
Neomycin
Penetrating Keratoplasty
Ophthalmic Solutions
Therapeutics
Framycetin
Gramicidin
Safety
Polymyxin B
Clinical Protocols
Infection
propamidine isethionate
Disease Progression
Rehabilitation
Clinical Trials
Guidelines

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Results of a trial of combined propamidine isethionate and neomycin therapy for acanthamoeba keratitis. / Hargrave, Sylvia L.; McCulley, James P; Husseini, Ziad.

In: Ophthalmology, Vol. 106, No. 5, 01.05.1999, p. 952-957.

Research output: Contribution to journalArticle

@article{35a70692d60f47449d88927670e70ba3,
title = "Results of a trial of combined propamidine isethionate and neomycin therapy for acanthamoeba keratitis",
abstract = "Purpose: To characterize patients with Acanthamoeba keratitis and to evaluate the safety and efficacy of propamidine isethionate 0.1{\%} ophthalmic solution (Brolene) when administered concomitantly with neomycin- polymyxin B-gramicidin ophthalmic solution (Neotricin) in the treatment of Acanthamoeba keratitis. Design: Prospective, noncomparative case series. Methods: The authors report the clinical characteristics and outcomes of patients who entered this multi-centered, open-label, clinical trial. Eighty-three patients with Acanthamoeba keratitis representing 87 infected eyes entered the trial. Results: Sixty (69{\%}) of the 87 eyes enrolled had data analyzed for treatment efficacy and safety. Of these 60 eyes, 50 (83{\%}) experienced treatment success. Thirty (60{\%}) patients successfully treated adhered to treatment protocol guidelines. Patients who broke protocol had disease exacerbation during the maintenance therapy phase. The only eyes lost/enucleated were 7 of 17 in which penetrating keratoplasty was performed before eradication of the infectious agent. Conclusion: Propamidine isethionate and neomycin are an effective treatment for Acanthamoeba keratitis. Penetrating keratoplasty should be performed only for visual rehabilitation and not to 'debulk' an active infection. The authors advocate treating patients with topical medications, mainly Brolene, until all organisms are eradicated. There should be no signs of infection for at least 3 months in the patients not receiving antiamebic medications before penetrating keratoplasty is performed.",
author = "Hargrave, {Sylvia L.} and McCulley, {James P} and Ziad Husseini",
year = "1999",
month = "5",
day = "1",
language = "English (US)",
volume = "106",
pages = "952--957",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Results of a trial of combined propamidine isethionate and neomycin therapy for acanthamoeba keratitis

AU - Hargrave, Sylvia L.

AU - McCulley, James P

AU - Husseini, Ziad

PY - 1999/5/1

Y1 - 1999/5/1

N2 - Purpose: To characterize patients with Acanthamoeba keratitis and to evaluate the safety and efficacy of propamidine isethionate 0.1% ophthalmic solution (Brolene) when administered concomitantly with neomycin- polymyxin B-gramicidin ophthalmic solution (Neotricin) in the treatment of Acanthamoeba keratitis. Design: Prospective, noncomparative case series. Methods: The authors report the clinical characteristics and outcomes of patients who entered this multi-centered, open-label, clinical trial. Eighty-three patients with Acanthamoeba keratitis representing 87 infected eyes entered the trial. Results: Sixty (69%) of the 87 eyes enrolled had data analyzed for treatment efficacy and safety. Of these 60 eyes, 50 (83%) experienced treatment success. Thirty (60%) patients successfully treated adhered to treatment protocol guidelines. Patients who broke protocol had disease exacerbation during the maintenance therapy phase. The only eyes lost/enucleated were 7 of 17 in which penetrating keratoplasty was performed before eradication of the infectious agent. Conclusion: Propamidine isethionate and neomycin are an effective treatment for Acanthamoeba keratitis. Penetrating keratoplasty should be performed only for visual rehabilitation and not to 'debulk' an active infection. The authors advocate treating patients with topical medications, mainly Brolene, until all organisms are eradicated. There should be no signs of infection for at least 3 months in the patients not receiving antiamebic medications before penetrating keratoplasty is performed.

AB - Purpose: To characterize patients with Acanthamoeba keratitis and to evaluate the safety and efficacy of propamidine isethionate 0.1% ophthalmic solution (Brolene) when administered concomitantly with neomycin- polymyxin B-gramicidin ophthalmic solution (Neotricin) in the treatment of Acanthamoeba keratitis. Design: Prospective, noncomparative case series. Methods: The authors report the clinical characteristics and outcomes of patients who entered this multi-centered, open-label, clinical trial. Eighty-three patients with Acanthamoeba keratitis representing 87 infected eyes entered the trial. Results: Sixty (69%) of the 87 eyes enrolled had data analyzed for treatment efficacy and safety. Of these 60 eyes, 50 (83%) experienced treatment success. Thirty (60%) patients successfully treated adhered to treatment protocol guidelines. Patients who broke protocol had disease exacerbation during the maintenance therapy phase. The only eyes lost/enucleated were 7 of 17 in which penetrating keratoplasty was performed before eradication of the infectious agent. Conclusion: Propamidine isethionate and neomycin are an effective treatment for Acanthamoeba keratitis. Penetrating keratoplasty should be performed only for visual rehabilitation and not to 'debulk' an active infection. The authors advocate treating patients with topical medications, mainly Brolene, until all organisms are eradicated. There should be no signs of infection for at least 3 months in the patients not receiving antiamebic medications before penetrating keratoplasty is performed.

UR - http://www.scopus.com/inward/record.url?scp=0033504307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033504307&partnerID=8YFLogxK

M3 - Article

C2 - 10328395

AN - SCOPUS:0033504307

VL - 106

SP - 952

EP - 957

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 5

ER -